ERBB2 and breast carcinoma: A study conducted by Hamid M. and Zhixiang W. on the effect of trastuzumab on the development of HER2-positive breast cancer cells revealed that this drug inhibits cancer cells proliferation by promoting the entering in G1 phase arrest, but did not have any effect on HER2 dimerization [150].